K
K. Martin Kortuem
Researcher at Mayo Clinic
Publications - 14
Citations - 601
K. Martin Kortuem is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 6, co-authored 7 publications receiving 502 citations.
Papers
More filters
Journal ArticleDOI
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
TL;DR: Cereblon downstream signaling will help to delineate the underlying mechanisms for IMiD action and eventually lead to development of new drugs with more specific anti-myeloma activities, and may also provide a biomarker to predict IMid response and resistance.
Journal ArticleDOI
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu,Esteban Braggio,Chang Xin Shi,K. Martin Kortuem,Laura Ann Bruins,Jessica Schmidt,Xiu Bao Chang,Paul R. Langlais,Moulun Luo,Patrick Jedlowski,Betsy LaPlant,Kristina Laumann,Rafael Fonseca,P. Leif Bergsagel,Joseph R. Mikhael,Martha Q. Lacy,Mia D. Champion,A. Keith Stewart +17 more
TL;DR: This study identifies CRBN-binding proteins and demonstrates that in addition to CRBN, IKZF1, and KPNA2, expression can predict survival outcomes.
Journal ArticleDOI
The clinical significance of cereblon expression in multiple myeloma
Steven R. Schuster,K. Martin Kortuem,Yuan Xiao Zhu,Esteban Braggio,Chang Xin Shi,Laura Ann Bruins,Jessica Schmidt,Greg J. Ahmann,Shaji Kumar,S. Vincent Rajkumar,Joseph R. Mikhael,Betsy LaPlant,Mia D. Champion,Kristina Laumann,Bart Barlogie,Rafael Fonseca,P. Leif Bergsagel,Martha Q. Lacy,A. Keith Stewart +18 more
TL;DR: It is demonstrated that low CRBN expression can predict resistance to IMiD monotherapy and is a predictive biomarker for survival outcomes.
Journal ArticleDOI
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease
Jan B. Egan,K. Martin Kortuem,Ahmet Kurdoglu,Tyler Izatt,Jessica Aldrich,Rebecca Reiman,Lori Phillips,Angela Baker,Chang Xin Shi,Jessica Schmidt,Winnie S. Liang,David Craig,John D. Carpten,A. Keith Stewart +13 more
TL;DR: An acquired truncating mutation of Cereblon (CRBN) is reported as well as point mutations in proteasome subunit G2 and the glucocorticoid receptor as an explanation for drug resistance for a 37-year-old IgG-kappa MM patient presenting with progressive, multi-drug refractory EMD.
Journal ArticleDOI
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.
Jan B. Egan,Michael T. Barrett,Mia D. Champion,Sumit Middha,Elizabeth Lenkiewicz,Lisa Evers,Princy Francis,Jessica Schmidt,Chang Xin Shi,Scott Van Wier,Sandra K Badar,Gregory J. Ahmann,K. Martin Kortuem,Nicole J. Boczek,Rafael Fonseca,David Craig,John D. Carpten,Mitesh J. Borad,A. Keith Stewart +18 more
TL;DR: This work is the first to report the entire genome of a well-differentiated liposarcoma with novel chromosomal rearrangements associated with amplification of therapeutically targetable genes such as MDM2 and DDR2.